Complex movement disorders induced by fluoxetine

Movement Disorders

Volumn 11, Issue 3, 1996, Pages 324-326

  Bharucha, Kersi J ^a   Sethi, Kapil D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Chorea; Dystonia; Fluoxetine; Myoclonus

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; DOXEPIN; FLUOXETINE;

ADULT; AGED; ARM; ARTICLE; CASE REPORT; CHOREA; CLINICAL FEATURE; DEPRESSION; DYSTONIA; FEMALE; HUMAN; JAW; LEG; MALE; MOTOR DYSFUNCTION; MYOCLONUS; PALATE; PRIORITY JOURNAL;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DYSKINESIA, DRUG-INDUCED; FEMALE; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION;

EID: 0029917877     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110318     Document Type: Article

References (31)

1. Gram LF. Drug therapy - fluoxetine. N Engl J Med 1994; 331:1354-1361.
2. Steur ENHJ. Increase of Parkinson disability after fluoxetine medication. Neurology 1993;43:211-213.
3. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry 1991; 148:1263.
4. Baldessarini RJ, Marsh E. Fluoxetine and side effects. Arch Gen Psychiatry 1990;47:191-192.
5. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989;146:1352-1353.
6. Brod TM. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989;146:1353.
7. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989;146:399-400.
8. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979;45:165-175.
9. Dave M. Fluoxetine-associated dystonia. Am J Psychiatry 1994;151:149.
10. Black B, Uhde TW. Acute dystonia and fluoxetine. J Clin Psychiatry 1992;53:327.
11. Recoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine. J Clin Psychiatry 1990;51:487.
12. Lipinsky JF, Mallya G, Zimmerman P, Pope HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989;50:339-342.
13. Stein MS. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1991;148:683.
14. Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine. Am J Psychiatry 1991;148:1403.
15. Eisenhauer G, Jermain DM. Fluoxetine and tics in an adolescent. Ann Pharmacother 1993;27:725-726.
16. Cunningham M, Cunningham K, Lydiard BR. Eye tics and subjective hearing impairment during fluoxetine therapy. Am J Psychiatry 1990;147:947.
17. Lilly Research Laboratories. Spontaneous reports of adverse events (postmarketing) through December 31, 1993 (Communication received from Eli Lilly and Company, December 1994).
18. Lauterbach EC. Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease. Mov Disord 1994;9:343-346.
19. Marsden CD, Hallet M, Fahn S. The nosology and pathophysiology of myoclonus. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworth, 1982:196-248.
20. Jankovic J, Pardo R. Segmental myoclonus: clinical and pharmacologic study. Arch Neurol 1986;43:1025-31.
21. Dubinsky R, Hallett M. Palatal myoclonus and facial involvement of other types of myoclonus. In: Jankovic J, Tolosa E, eds. Facial dyskinesias. New York: Raven Press, 1988:263-278.
22. Lapresle J. Palatal myoclonus. In: Fahn S, Marsden CD, Van Woert MH, eds. Myoclonus. New York: Raven Press, 1986:265-273. (Advances in neurology; vol 43).
23. Deuschl G, Mischke G, Schenck E, Schulte-Monting J, Lucking CH. Symptomatic and essential rhythmic palatal myoclonus. Brain 1990;113:1645-1672.
24. Klawans HL, Goetz C, Weiner WJ. 5-Hydroxytryptophan-induced myoclonus in guinea pigs and the possible role of serotonin in infantile myoclonus. Neurology 1973;23:1234-1240.
25. Wolfson LI, Thai LJ, Brown LL. Serotonin models of myoclonus in the guinea pig and rat. In: Fahn S, Marsden CD, Van Woert MH, eds. Myoclonus. New York: Raven Press, 1986:519-527. (Advances in neurology; vol 43).
26. Ritchie EC, Bridenbaugh RH, Jabbari B. Acute generalized myoclonus following buspirone administration. J Clin Psychiatry 1988;49:242-243.
27. Geyer MA, Puerto A, Dawsey WJ, Knapp S, Bullard WP, Mandell AJ. Histologic and enzymatic studies of the mesolimbic and mesostriatal serotoninergic pathways. Brain Res 1976;106:241-256.
28. Coplan JD, German JM. Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome [Letter]. Am J Psychiatry 1993;150:837.
29. Lemberger L, Rowe H, Carmichael R, et al. Fluoxetine, a selective serotonin uptake inhibitor. Clin Pharmacol Ther 1978;23:421-429.
30. Brøsen K, Gram LF. Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-547.
31. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248.